Genomic stratification of multiple myeloma treated with novel agents

References

• Raab MS, Podar K, Breitkreutz I, . Multiple myeloma. Lancet 2009;374:324–339.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegal R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H. Role of genetics in prognostication of myeloma. Best Res Clin Haematol 2007;20:625–635.
   PubMed Web of Science ®Google Scholar
• Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008;61:832–836.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Chesi M, Nardini E, . Promiscuous translocation into immunoglobulin heavy chain switch regions in multiple myelomas. Proc Natl Acad Sci USA 1996;93:13931–13936.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Brigaudeau C, Talmant P, . High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;24:9–15.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333–6338.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Malard F, Campion L, . Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011;117:2009–2011.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569–4575.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, . The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64–68.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi XY, Stewart AK. t(11;14) does not predict long-term survival in myeloma. Leukemia 2005;19:1078–1079.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–2221.
   PubMed Web of Science ®Google Scholar
• Chang H, Bouman D, Boerkoel CF, . Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia 1999;13:105–109.
   PubMed Web of Science ®Google Scholar
• Facon T, Avet-Loiseau H, Guillerm G, . Chromosome 13 abnormalities identified by FISH analysis and serum [beta]2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566–1571.
   PubMed Web of Science ®Google Scholar
• Fassas AB, Spencer T, Sawyer J, . Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041–1047.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Harrington D, Oken MM, . Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002;62:715–720.
   PubMed Web of Science ®Google Scholar
• Dewald GW, Therneau T, Larson D, . Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of multiple myeloma. Blood 2005;106:3553–3558.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Yi QL, . p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358–360.
   PubMed Web of Science ®Google Scholar
• Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009–1011.
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, . Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004;127:280–284.
   PubMed Web of Science ®Google Scholar
• Sawyer JR, Waldron JA, Jagannath S, . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41–49.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10:117–126.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108: 1724–1732.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Trieu Y, . Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135:486–491.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, . Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034–2040.
   PubMed Web of Science ®Google Scholar
• Nemec P, Zemanova Z, Greslikova H, . Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548–554.
   PubMed Web of Science ®Google Scholar
• Zhan F, Colla S, Wu X, . CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007:109:4995–5001.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Li C, Magrangeas F, . Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009;27:4585–4590.
   PubMed Web of Science ®Google Scholar
• Walker BA, Leone PE, Jenner MW, . Integration of global SNP-based mapping and expression array reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733–1743.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Jiang A, . 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010;45:117–121.
   PubMed Web of Science ®Google Scholar
• Mailand N, Lukas C, Kaiser BK, . Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation. Nat Cell Biol 2002;4:317–322.
   PubMed Web of Science ®Google Scholar
• Paulsen MT, Starks AM, Derheimer FA, . The p53-targeting human phosphatase hCdc14A interacts with the CdkI/cyclin B complex and is differentially expressed in human cancers. Mol Cancer 2006;5:25.
   PubMed Web of Science ®Google Scholar
• Leone PE, Walker BA, Jenner MW, . Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008;14:6033–6041.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gertz MA, Chung TH, . Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia 2010;24:833–842.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349–360.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Sonneveld P, . Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–157.
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, . Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of chromosome 13q-deletion. Leukemia 2007;21:164–168.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779–782.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, . Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res 2011;35:95–98.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, . Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518–3525.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhou Y, Haessler J, . TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009;147:347–351.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, . Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630–4634.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, . Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Podar K, . Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607–612.
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Macdonald CD, . Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166–1172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, . A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, . Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, . Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JP, Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623–628.
   PubMed Web of Science ®Google Scholar
• Chang H, Jiang A, Qi C, . Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma 2010;51:2084–2091.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, . Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769–1778.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, . Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114: 518–521.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, . Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679–686.
   PubMed Web of Science ®Google Scholar